Skip to main content
ABT logo

Abbott Laboratories

ABTNYSEHealthcareMedical Devices

$104.68Today:- (-)1Y −17.98%

As of Oct 15, 2026 close

Market cap
$182.46B
P/E (TTM)
33.63
Forward P/E
67.40
Dividend yield
2.41%
52-week range
$81.97$132.03
Volume (live)
-
Avg. volume (3M)
9.06M

Abbott Laboratories (ABT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Abbott Laboratories generated $9.57B of operating cash flow and spent $2.17B on capital expenditures. That left free cash flow of $7.39B, up 16.4% from $6.35B a year earlier, or 16.7% of revenue. It returned $5.01B to shareholders through $4.12B in dividends and $893.00M in share buybacks.

Abbott Laboratories Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Abbott Laboratories (ABT) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income6.5213.405.726.937.074.503.692.370.48
Depreciation & Amortization3.123.223.243.273.543.333.013.283.02
Deferred Income Tax0.000.000.000.000.000.000.000.29-1.16
Stock Based Compensation0.660.670.640.690.640.550.520.480.41
Change in Working Capital-0.80-9.22-2.48-1.52-0.77-0.89-1.33-0.151.92
Change in Accounts Receivable-0.65-0.69-0.36-0.07-0.38-0.92-0.28-0.19-0.21
Change in Inventory0.20-0.06-0.23-1.41-0.46-0.49-0.59-0.510.25
Change in Accounts Payable0.950.36-0.760.041.291.770.220.750.62
Change in Other Working Capital-1.30-0.80-1.13-0.08-1.22-1.24-0.68-0.191.26
Other Operating Activities0.070.480.130.220.060.430.250.030.91
Net Cash from Operating Activities9.578.567.269.5810.537.906.146.305.57
Investing Activities
Capital Expenditures-2.17-2.21-2.20-1.78-1.89-2.18-1.64-1.39-1.14
Acquisitions-0.110.00-0.840.05-0.190.02-0.120.05-8.44
Purchases of Investments-0.17-0.17-0.16-0.19-0.17-0.08-0.10-0.13-0.21
Sales/Maturities of Investments0.000.030.040.150.080.010.020.070.13
Other Investing Activities0.020.010.020.020.030.020.030.050.04
Net Cash from Investing Activities-2.42-2.34-3.13-1.74-2.01-2.22-1.82-1.36-9.62
Financing Activities
Debt Repayment-1.61-0.66-2.48-0.75-0.05-0.05-1.60-8.45-1.91
Common Stock Issued0.400.260.000.170.000.000.000.000.00
Common Stock Repurchased-0.89-1.30-1.23-3.80-2.30-0.40-0.72-0.24-0.83
Dividends Paid-4.12-3.84-3.56-3.31-3.20-2.56-2.27-1.97-1.85
Other Financing Activities-0.08-0.100.170.050.260.230.300.27-1.76
Net Cash from Financing Activities-6.31-5.40-7.09-7.64-5.49-2.78-4.29-10.39-5.28
Summary
Effect of Forex Changes on Cash0.07-0.10-0.02-0.12-0.070.07-0.02-0.120.12
Net Change in Cash0.910.72-2.990.083.032.980.02-5.56-9.21
Cash at Beginning of Period7.626.909.889.806.843.863.849.4118.62
Cash at End of Period8.527.626.909.889.806.843.863.849.41
Free Cash Flow7.406.355.067.808.655.724.504.914.44
Supplemental Disclosures
Interest Paid-0.600.660.560.54----
Income Taxes Paid-1.721.481.861.94----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Abbott Laboratories Cash Flow

What is Abbott Laboratories's free cash flow?

Abbott Laboratories generated free cash flow of $7.39B in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $9.57B minus $2.17B of capital expenditures. That was up 16.4% from $6.35B a year earlier. Free cash flow equaled 16.7% of revenue.

How much does Abbott Laboratories spend on capital expenditures?

Abbott Laboratories spent $2.17B on capital expenditures in fiscal 2025, compared with $2.21B a year earlier. That equals 22.7% of operating cash flow.

Does Abbott Laboratories pay dividends or buy back shares?

Yes. In fiscal 2025 Abbott Laboratories returned $4.12B in dividends and $893.00M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition